PDCD1 and head and neck squamous cell carcinoma: Anti‐PD‐1 therapy was approved by the FDA in the treatment of recurrent and metastatic HNSCC patients.[21, 22] However, the low ORR of anti‐PD‐1 therapy alone in patients with HNSCC indicates a significant number of patients do not experience clinical benefits, suggesting that combined treatment strategies may improve clinical benefits.